{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dopamine
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Romergoline (FCE 23884) is an ergoline derivative and a dopamine receptor agonist and antagonist. Its action depends on the functional state of the biological substrate, mostly related to the presence or absence of dopamine. In healthy animals, it behaves as a full dopamine antagonist, but in denervated models it behaves as an agonist. Therefore, romergoline was suggested to be potentially useful in both psychotic states and extrapyramidal diseases. In Parkinson patients, the degree of dopamine receptor stimulation was found to be insufficient to improve symptoms. Information about further development of romergoline is not available.
Status:
Investigational
Source:
INN:clopimozide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Clopimozide is a typical antipsychotic drug, developed by Janssen Pharmaceutica. Clopimozide belongs to diphenylbutylpiperidine class of neuroleptics, and possess an extremely long duration of action. The drug acts by binding to dopamine receptors and by inhibition of calcium channels. In a clinical trial, clopimozide exhibited a marked effect on schizophrenic target symptoms, with an absence of sedation and a low degree of extrapyramidal side-effects. Despite positive results, the drug was never marketed.
Status:
Investigational
Source:
INN:tepirindole [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tepirindole (also known as HR-592), an indole derivative has a high affinity for DA, 5-HT and NE receptors but has little properties to cause catalepsy. Animal experiments have shown that this compound could alleviate the adverse effect of neuroleptics such as haloperidol. Information about the current development of tepirindole is not available.
Status:
Investigational
Source:
Eur J Neurosci. Aug 2015;42(4):2028-35.: Not Applicable Human clinical trial Completed Parkinson Disease/complications
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT01246908: Phase 2 Interventional Completed Treatment Resistant Depression
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Spiroxatrine is a drug which acts as a selective antagonist at both the 5-HT1A receptor and the α2 adrenergic receptor. Spiroxatrine was identified as a moderately potent but non-selective agonist at the human nociceptin/orphanin FQ receptor, ORL1
Status:
Investigational
Class (Stereo):
CHEMICAL (UNKNOWN)
Etrabamine is a potent agonist of dopamine D2 receptors. It was being studied in the treatment of Parkinson's disease, however, its development has been discontinued.
Status:
Investigational
Source:
NCT00620568: Phase 1 Interventional Terminated Healthy
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Adoprazine (SVL-313) is a full 5-HT1A receptor agonist and full D2/3 receptor antagonist possessing characteristics of an atypical antipsychotic, representing a potential novel treatment for schizophrenia and bipolar disorder. This drug together with some others, e.g. Mazapertine succinate, PF-217830 was discontinued from clinical trials due to either non-optimal pharmacokinetic properties or insufficient therapeutical efficacy.
Status:
Investigational
Source:
Int Pharmacopsychiatry. 1978;13(3):138-50.: Not Applicable Human clinical trial Completed Schizophrenia/physiopathology
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Butaclamol is an antipsychotic drug, which was studied for the treatment of schizophrenia. This drug has never marketed and now is used in research, because of its action as a dopamine receptor-blocking agent. Butaclamol consists of the two forms: (-)-butaclamol, an inactive drug and (+)-butaclamol, a potent neuroleptic drug.
Class (Stereo):
CHEMICAL (RACEMIC)
ISOSULPRIDE, a benzamide derivative, is an atypical neuroleptic.
